TERN Terns Pharmaceuticals, Inc.
Price Chart
Executive Summary
Merck will acquire Terns Pharmaceuticals for $53.00 per share in cash, representing a total equity value of $6.7 billion and a 31-42% premium to Terns' recent trading prices. The deal is driven by Terns' lead oncology candidate, TERN-701, a novel allosteric BCR::ABL1 inhibitor in development for chronic myeloid leukemia (CML), which Merck sees as a potential best-in-class therapy. The transaction is expected to close in Q2 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Actionable Insight
Traders should monitor the tender offer process and Hart-Scott-Rodino clearance timeline; TERN stock is likely to trade near the $53 offer price pending deal closure. The $2.35 per share earnings impact for Merck may pressure its near-term EPS, but long-term oncology pipeline diversification could support valuation. Watch for any competing bids or shareholder litigation risks.
Key Facts
- Merck is acquiring Terns for $53.00 per share in cash, a 31% premium to the 60-day and 42% to the 90-day volume-weighted average price.
- Total equity value of the deal is $6.7 billion, with net value of $5.7 billion after adjusting for acquired cash.
- TERN-701, Terns' lead asset, is an investigational oral allosteric BCR::ABL1 inhibitor in Phase 1/2 development for CML, with FDA Orphan Drug Designation granted in March 2024.
- Clinical data show promising major and deep molecular responses by week 24, including in heavily pretreated patients, with a favorable safety profile.
- The acquisition is structured as a tender offer and is expected to close in Q2 2026, subject to antitrust clearance and shareholder approval.
- Merck will record a $5.8 billion charge in Q2 2026 related to the acquisition, impacting both GAAP and non-GAAP earnings by $2.35 per share.
Financial Impact
$6.7 billion total equity value, $5.8 billion charge to Merck in Q2 2026
Risk Factors
- Deal may not close if a majority of Terns shareholders do not tender their shares.
- Regulatory delays or objections under antitrust review could push closing beyond Q2 2026.
- Clinical development risk: TERN-701 remains in early-stage trials and may not meet efficacy or safety endpoints in later studies.
- Merck's $5.8 billion charge could impact investor sentiment on near-term profitability.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262042 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
15-12G
| $52.97 awaiting T+1 | awaiting T+1 | — | — |
|
May 8, 2026
4w ago
|
EFFECT
| $52.95 $52.95 | · 0.00% | ▼ −0.23% | — |
|
May 5, 2026
5w ago
|
8-K
| $52.95 $52.95 | · 0.00% | ▼ −1.38% | — |
|
May 5, 2026
5w ago
|
25-NSE
| $52.95 $52.95 | · 0.00% | ▲ +1.38% | — |
|
Apr 27, 2026
6w ago
|
8-K
| $52.95 $52.94 | ▼ −0.02% | ▲ +0.47% | — |
|
Apr 27, 2026
6w ago
|
Press Release
| $52.95 $52.94 | ▼ −0.02% | ▲ +0.47% | — |
|
Mar 25, 2026
10w ago
|
Press Release
| $52.86 $53.17 | ▲ +0.59% | ▲ +2.36% | — |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $42.03 $41.51 | ▼ −1.24% | ▼ −0.32% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access